Abbott Laboratories (NYSE: ABT) on Thursday introduced monetary outcomes for the fourth quarter of 2024, reporting a rise in gross sales and adjusted revenue.
Whole reported gross sales elevated 7.2 year-over-year to $10.9 billion within the December quarter, exceeding estimates. Natural gross sales for the underlying base enterprise grew 10.1%.
Adjusted earnings moved as much as $1.34 per share in This autumn from $1.19 per share within the year-ago quarter and matched Wall Road’s expectations. Unadjusted revenue rose sharply to $9.23 billion or $5.27 per share within the fourth quarter from $1.60 billion or $0.91 per share in This autumn 2023, reflecting a major tax profit.
(this story can be up to date shortly with infographic)
